MedTrace Logo

ATP Expression in Lymphocytes of MS Patients by Means of "ImmuKnow®" Assay.

NCT00618267 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2010-03-05

No results posted yet for this study

Summary

The purpose of this study is to see if we can find a new way to test how certain Multiple Sclerosis (MS) medications work in the body and to better understand how the medicines change certain substances (cells) found in the immune (protective) system.

Blood test will be drawn by doing the following:

* Use a new method called the "Immuknow®" Test to see if this method will help to better understand how MS medicines work.
* Measure certain levels of immune cells in a new way, to see if it this will help to understand the body's response to MS medicines.

These methods will test those with MS who are not taking any MS medications, to help us compare the results.

About 100 subjects will be enrolled in this study at the Partners Multiple Sclerosis Center at Brigham and Women's Hospital. Biogen Idec, Inc. of Cambridge, MA, is paying for this study to be done.

Conditions

Sponsors & Collaborators

  • Elan Pharmaceuticals

    collaborator INDUSTRY

  • Biogen

    lead INDUSTRY

Principal Investigators

  • Samia J Khoury, MD · Harvard Medical School, Brigham and Women's Hospital - Partners MS Center

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00618267 on ClinicalTrials.gov